Targeting the transforming growth factor-β signalling pathway in metastatic cancer

• Published in: European journal of cancer (1990) Vol. 46; no. 7; pp. 1232 - 1240
• Main Authors: Korpal, Manav, Kang, Yibin
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2010
• Subjects: Animals; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - pharmacology; Antisense Elements (Genetics) - therapeutic use; Cancer; Cell Transformation, Neoplastic - metabolism; Combined Modality Therapy; Disease Progression; Hematology, Oncology and Palliative Medicine; Humans; Metastasis; Mice; Molecular therapeutics; Neoplasm Metastasis - drug therapy; Neoplasm Metastasis - physiopathology; Neoplasm Proteins - immunology; Neoplasm Proteins - physiology; Signal Transduction - drug effects; TGF-β; Transforming Growth Factor beta - antagonists & inhibitors; Transforming Growth Factor beta - immunology; Transforming Growth Factor beta - physiology; TGF-β; Metastasis; Molecular therapeutics; Cancer
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/j.ejca.2010.02.040

Abstract Transforming growth factor (TGF)-β signalling plays a dichotomous role in tumour progression, acting as a tumour suppressor early and as a pro-metastatic pathway in late-stages. There is accumulating evidence that advanced-stage tumours produce excessive levels of TGF-β, which acts to promote tumour growth, invasion and colonisation of secondary organs. In light of the pro-metastasis function, many strategies are currently being explored to antagonise the TGF-β pathway as a treatment for metastatic cancers. Strategies such as using large molecule ligand traps, reducing the translational efficiency of TGF-β ligands using antisense technology, and antagonising TGF-β receptor I/II kinase function using small molecule inhibitors are the most prominent methods being explored today. Administration of anti-TGF-β therapies alone, or in combination with immunosuppressive or cytotoxic therapies, has yielded promising results in the preclinical and clinical settings. Despite these successes, the temporal- and context-dependent roles of TGF-β signalling in cancer has made it challenging to define patient subgroups that are most likely to respond, and the therapeutic regimens that will be most effective in the clinic. Novel mouse models and diagnostic tools are being developed today to circumvent these issues, which may potentially expedite anti-TGF-β drug development and clinical application.